Ameriprise’s BridgeBio Pharma BBIO Stock Holding History

Ameriprise’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$116M	Buy	1,551,663 +303,142	+24%	+$21.2M	0.02%	547
2026 Q1	$92.7M	Buy	1,248,521 +406,985	+48%	+$29.5M	0.02%	584
2025 Q4	$64.4M	Buy	841,536 +40,855	+5%	+$2.68M	0.01%	751
2025 Q3	$41.6M	Buy	800,681 +13,637	+2%	+$665K	0.01%	997
2025 Q2	$34M	Sell	787,044 -254,891	-24%	-$9.27M	0.01%	1063
2025 Q1	$36M	Buy	1,041,935 +608,856	+141%	+$20.5M	0.01%	998
2024 Q4	$11.9M	Sell	433,079 -17,302	-4%	-$447K	﹤0.01%	1669
2024 Q3	$11.5M	Buy	450,381 +415,606	+1,195%	+$10.9M	﹤0.01%	1673
2024 Q2	$881K	Buy	34,775 +45	+0.1%	+$1.23K	﹤0.01%	3200
2024 Q1	$1.07M	Sell	34,730 -80	-0.2%	-$2.72K	﹤0.01%	3133
2023 Q4	$1.41M	Buy	34,810 +300	+0.9%	+$9.01K	﹤0.01%	3048
2023 Q3	$910K	Sell	34,510 -1,645	-5%	-$46.7K	﹤0.01%	3184
2023 Q2	$622K	Sell	36,155 -1,465	-4%	-$22K	﹤0.01%	3358
2023 Q1	$624K	Sell	37,620 -23,097	-38%	-$269K	﹤0.01%	3340
2022 Q4	$463K	Sell	60,717 -530	-0.9%	-$5.07K	﹤0.01%	3436
2022 Q3	$609K	Buy	61,247 +42,052	+219%	+$437K	﹤0.01%	3313
2022 Q2	$174K	Buy	+19,195	New	+$161K	﹤0.01%	3706
2022 Q1	–	Sell	-40,372	Closed	-$674K	–	3939
2021 Q4	$674K	Sell	40,372 -1,440	-3%	-$60.9K	﹤0.01%	3419
2021 Q3	$1.96M	Buy	41,812 +3,293	+9%	+$177K	﹤0.01%	2881
2021 Q2	$2.35M	Buy	38,519 +3,308	+9%	+$189K	﹤0.01%	2858
2021 Q1	$2.17M	Sell	35,211 -7,391	-17%	-$484K	﹤0.01%	2826
2020 Q4	$3.03M	Sell	42,602 -1,637	-4%	-$79K	﹤0.01%	2582
2020 Q3	$1.66M	Sell	44,239 -2,563	-5%	-$80.6K	﹤0.01%	2763
2020 Q2	$1.53M	Sell	46,802 -11,690	-20%	-$356K	﹤0.01%	2733
2020 Q1	$1.7M	Buy	58,492 +29,519	+102%	+$915K	﹤0.01%	2564
2019 Q4	$1.02M	Buy	28,973 +1,429	+5%	+$39.6K	﹤0.01%	3045
2019 Q3	$591K	Buy	27,544 +2,429	+10%	+$67.2K	﹤0.01%	3244
2019 Q2	$677K	Buy	+25,115	New	+$685K	﹤0.01%	3219

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Ameriprise's BBIO Position: Q2 2026 in Review

Ameriprise increased its BridgeBio Pharma (BBIO) stake by 24% in Q2 2026, buying an estimated $21.2M and bringing the position to 1,551,663 shares worth $116M. The position accounts for 0.02% of the portfolio, ranked #547.

Ameriprise first reported a position in BBIO in Q2 2019 and has held it in 28 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Ameriprise held 1,551,663 shares of BridgeBio Pharma worth $116M as of Q2 2026.
Ameriprise bought 303,142 BridgeBio Pharma shares in Q2 2026, an estimated $21.2M.
BridgeBio Pharma made up 0.02% of Ameriprise's portfolio in Q2 2026, its #547 holding.
Ameriprise first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 28 quarters since.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.